Type of outcome measures: The search strategy MEDLINE (OVID)
|
|
|
- Shanon Tucker
- 8 years ago
- Views:
Transcription
1 Types of participants: Inclusion criteria: Randomized controlled trials, examining effect of Renin-angiotensin system blockade on the renal and cardiovascular events in patients with chronic kidney disease for more than six months. Exclusion criteria: 1) non- RCTs 2) Trials did not meet the criteria of CKD (Chronic kidney disease was defined as CKD as per the KDOQI guidelines) 3) Trials without the intervening of ACEI and/or ARB or Aliskiren. 4) Trials without renal events or cardiovascular events or other adverse events. Type of intervention: Use the Rennin-angiotensin system blockade agent ACE-Is or/and ARBs or rennin-inhibiter agent Aliskiren. Type of outcome measures: 1) End-stage kidney disease 2) Doubling of serum creatinine level 3) 50% or more decline in GFR 4) Kidney failure (defined as a composite of any of the following; doubling of serum creatinine level, 50% decline in GFR, or end-stage kidney disease) 5) Fatal/non fatal heart failure 6) Fatal/non fatal stroke 7) Fatal/non fatal myocardial infarction 8) Major cardiovascular event including fatal/non fatal myocardial infarction, heart failure, stroke 9) Cardiovascular mortality 10) All-cause Mortality 11) Any adverse events, including adverse event related to hyperkalemia cough angioedema oedema hypotension serious adverse events. 12) Proteinuria 13) Serum creatinine 14) GFR 15) SBP and DBP 16) Other cardiovascular disorder The search strategy MEDLINE (OVID) 1. exp Angiotensin-Converting Enzyme Inhibitors/ 2. angiotensin converting enzyme inhibit$.tw. 3. (ace adj2 inhibit$).tw. 4. (ACE or ACE1 or ACEI or ACE-I or ACEs). 5.alacepril.tw. 6.benazepril.tw. 7.benazeprila.tw. 8. captopril.tw. 9. enalapril.tw.
2 10. cilazapril.tw. 11. enalaprilat.tw. 12. fosinopril.tw. 13. lisinopril.tw. 14. perindopril.tw. 15. ramipril.tw. 16. benazeprilat.tw. 17. ceranapril.tw. 18. cilazaprilat.tw. 19. delapril.tw. 20.fosinoprilic acid.tw. 21. imidapril.tw. 22. libenzapril.tw. 23. quinaprilat.tw. 24. ramiprilat.tw. 25. rentiapril.tw. 26. saralasin.tw. 27. spirapril.tw. 28.temocapril hydrochloride 29. teprotide.tw. 30. zofenopril.tw. 31. trandolapril.tw. 32.quinapril.tw. 33.moexipril.tw. 34.ceronapril.tw. 35. deacetylalacepril.tw. 36.fosinopril$. 37.losartan.tw. 38.azilsartan.tw. 39.elisartan.tw 40.embusartan.tw. 41.forasartan.tw. 42.saprisartan.tw. 43.tasosartan.tw. 44.vasvalsartan.tw. 45.zolasartan.tw. 46.miardis.tw. 47.cozaar.tw. 48.atacand.tw. 49.teveten.tw. 50.avapro.tw. 51.micardis.tw. 52.avalide.tw. 53.aprovel.tw.
3 54.amias.tw. 55.diovan.tw. 56.olmetec.tw. 57. irbesartan.tw. 58. candesartan.tw. 59. eprosartan.tw. 60. valsartan.tw. 61. olmesartan.tw. 62. telmisartan.tw. 63. (ace adj2 inhibitor$).tw. 64. (angiotensin adj2 receptor antagonist$).tw. 65.ARB.tw. 66.Angiotensin 2 Receptor Antagonist.tw. 67.Angiotensin Receptor Antagonist.tw. 68.Angiotensin II Antagonist.tw. 69.AT 2 receptor blocker.tw. 70.AT 2 receptor antagonist.tw. 71. aliskiren.tw. 72. or/ (kidney disease or renal disease).tw. 74. Kidney Failure, Chronic/ 75. Kidney Failure/ 76. (chronic kidney or chronic renal).tw. 77. Renal Insufficiency, Chronic/ or Kidney Failure, Chronic/ 78. Uremia/ 79. (CKD or CKF or CRF or ESRD or ESKF or ESRF or ESKD or CRD).tw. 80. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw. 81. renal replacement therapy/ or exp renal dialysis/ or exp hemofiltration/ 82. (predialysis or dialysis).tw. 83. (haemodialysis or haemodialysis).tw. 84. (hemofiltration or haemofiltration).tw. 85. (hemodiafiltration or haemodiafiltration).tw. 86. (CAPD or CCPD or APD or PD).tw. 87. exp Proteinuria/ 88. proteinuria.tw. 89.albuminuria.tw. 90.macroalbuminuria.tw. 91.microalbuminuria.tw. 92.(urin$ adj6 (protein$ or albumin$ or microalbumin$)).tw. 93. or/ Randomized controlled trial.pt. 95.Controlled clinical trial.pt 96. Randomized.tw. 97. Placebo.tw.
4 98.Drug therapy/ 99.Randomly.tw. 100.Trial.tw. 101.Groups.tw. 102.(random$ adj5 trial$).tw (random$ adj5 allocation$).tw. 104.(Blind$ adj5 method$).tw. 105.or/ and 93 and 105 EMBASE 1. exp Angiotensin-Converting Enzyme Inhibitors 2. angiotensin adj2 receptor antagonist$ 3. Angiotensin 2 Receptor Antagonist 4. Angiotensin Receptor Antagonist 5. Angiotensin II Antagonist 6. AT 2 receptor blocker 7. AT 2 receptor antagonist 8. fosinopril$ 9.losartan 10.azilsartan 11.elisartan 12.embusartan 13.forasartan 14.saprisartan 15.tasosartan 16.vasvalsartan 17.zolasartan 18.miardis 19.cozaar 20.atacand 21.teveten 22.avapro 23.micardis 24.avalide 25.aprovel 26.amias 27.diovan 28.olmetec 29. irbesartan 30. candesartan 31. eprosartan 32. valsartan 33. olmesartan
5 34. telmisartan 35. ace adj2 inhibitor$ 36. angiotensin converting enzyme inhibit$ 37. ace adj2 inhibit$ 38. ACE or ACE1 or ACEI or ACE-I or ACE 39.alacepril 40.benazepril 41.benazeprila 42. captopril 43. enalapril 44. cilazapril 45. enalaprilat 46. fosinopril 47. lisinopril 48. perindopril 49. ramipril 50. benazeprilat 51. ceranapril 52. cilazaprilat 53. delapril 54. fosinoprilic acid 55. imidapril 56. libenzapril 57. quinaprilat 58. ramiprilat 59. rentiapril 60. saralasin 61. spirapril 62.temocapril hydrochloride 63. teprotide 64. zofenopril 65. trandolapril 66.quinapril 67.moexipril 68.ceronapril 69. deacetylalacepril 70. aliskiren 71.or/ kidney disease or renal disease 73. Kidney Failure, Chronic 74. Kidney Failure 75. chronic kidney or chronic renal 76. Uremia 77. CKD or CKF or CRF or ESRD or ESKF or ESRF or ESKD or CRD
6 78. end-stage renal or end-stage kidney or endstage renal or endstage kidney 79. predialysis or dialysis 80. haemodialysis or haemodialysis 81. hemodiafiltration or haemodiafiltration 82. CAPD or CCPD or APD or PD 83. exp Proteinuria 84. proteinuria 85. macroalbuminuria 86. microalbuminuria 87. albuminuria 88. or/ Randomized controlled trial 90. Controlled clinical trial 91. blind and method 92. randomized and controlled and trial 93. random and allocation 94. or/ and 88 and 94 COCHRANE CONTROLLED TRIALS 1. (kidney disease or renal disease).tw. 2. Kidney Failure, Chronic/ 3. Kidney Failure/ 4. (chronic kidney or chronic renal).tw. 5. Renal Insufficiency, Chronic/ or Kidney Failure, Chronic/ 6. Uremia/ 7. (CKD or CKF or CRF or ESRD or ESKF or ESRF or ESKD or CRD).tw. 8. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw. 9. renal replacement therapy/ or exp renal dialysis/ or exp hemofiltration/ 10. (predialysis or dialysis).tw. 11. (haemodialysis or haemodialysis).tw. 12. (hemofiltration or haemofiltration).tw. 13. (hemodiafiltration or haemodiafiltration).tw. 14. (CAPD or CCPD or APD or PD).tw. 15. exp Proteinuria/ 16. proteinuria.tw. 17. albuminuria.tw. 18. macroalbuminuria.tw. 19. microalbuminuria.tw. 20. (urin$ adj6 (protein$ or albumin$ or microalbumin$)).tw. 21. or/ exp Angiotensin-Converting Enzyme Inhibitors/ 23. angiotensin converting enzyme inhibit$.tw. 24. (ace adj2 inhibit$).tw.
7 25. (ACE or ACE1 or ACEI or ACE-I or ACEs).tw. 26. alacepril.tw. 27. benazepril.tw. 28. benazeprila.tw. 29. captopril.tw. 30. enalapril.tw. 31. cilazapril.tw. 32. enalaprilat.tw. 33. fosinopril.tw. 34. lisinopril.tw. 35. perindopril.tw. 36. ramipril.tw. 37. benazeprilat.tw. 38. ceranapril.tw. 39. cilazaprilat.tw. 40. delapril.tw. 41.fosinoprilic acid.tw. 42. imidapril.tw. 43. libenzapril.tw. 44. quinaprilat.tw. 45. ramiprilat.tw. 46. rentiapril.tw. 47. saralasin.tw. 48. spirapril.tw. 49.temocapril hydrochloride 50. teprotide.tw. 51. zofenopril.tw. 52. trandolapril.tw 53. quinapril.tw. 54. moexipril.tw. 55. ceronapril 56. deacetylalacepril.tw. 57. fosinopril$. 58. losartan.tw. 59. azilsartan.tw. 60. elisartan.tw 61. embusartan.tw. 62. forasartan.tw. 63. saprisartan.tw. 64. tasosartan.tw. 65. vasvalsartan.tw. 66. zolasartan.tw. 67. miardis.tw. 68. cozaar.tw.
8 69. atacand.tw. 70. teveten.tw. 71. avapro.tw. 72. micardis.tw. 73. avalide.tw. 74. aprovel.tw. 75. amias.tw. 76. diovan.tw. 77. olmetec.tw. 78. irbesartan.tw. 79. candesartan.tw. 80. eprosartan.tw. 81. valsartan.tw. 82. olmesartan.tw. 83. telmisartan.tw. 84. (ace adj2 inhibitor$).tw. 85. (angiotensin adj2 receptor antagonist$).tw. 86. ARB.tw. 87. Angiotensin 2 Receptor Antagonist.tw. 88. Angiotensin Receptor Antagonist.tw. 89. Angiotensin II Antagonist.tw. 90. AT 2 receptor blocker.tw. 91.AT 2 receptor antagonist.tw. 92. aliskiren.tw. 93. or/ Randomized controlled trial.pt. 95. Controlled clinical trial.pt 96. Randomized.tw. 97. Placebo.tw. 98. Drug therapy/ 99. Randomly.tw. 100.Trial.tw Groups.tw (random$ adj5 trial$).tw (random$ adj5 allocation$).tw (Blind$ adj5 method$).tw or/ and 93 and 105
COMPARING TWO KINDS OF BLOOD PRESSURE PILLS:
COMPARING TWO KINDS OF BLOOD PRESSURE PILLS: ACEIs and ARBs A Guide for Adults Fast Facts ACEIs and ARBs are two of the many kinds of blood pressure pills. Both kinds of pills (ACEIs and ARBs) do a good
Special Communication
Clinical Review & Education Special Communication 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National
Surgery Scheduling Process
Pre-op Instructions Our surgery scheduler will contact you within one week of leaving our office. Your availability for surgery will be determined during that phone call. Our scheduler will then call the
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Prevention and management of chronic kidney disease in type 2 diabetes
162..194 NEPHROLOGY 2010; 15, S162 S194 doi:10.1111/j.1440-1797.2010.01240.x Prevention and management of chronic kidney disease in type 2 diabetes Date written: April 2009nep_1240 Final submission: April
In many diabetes units, people with type
Renal Microalbuminuria: Screening and management in type 2 diabetes Julia Arundale Introduction In many diabetes units, patients with type 1 or type 2 diabetes are screened for proteinuria. Screening for
Hypertension Management in Hypertensive Adults with Diabetes in Primary Care setting
Hypertension Management in Hypertensive Adults with Diabetes in Primary Care setting Pratik P. Rane, MBA; Archita Bhansali; Ruta Sawant; Dr. Rajender R. Aparasu, MPharm, PhD, FAPhA. Introduction: Hypertension
Diabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
PROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT
DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT Diabetic nephropathy affects people with either type 1 or type 2 diabetes mellitus.
Blood Pressure Lowering in Type 2 Diabetes A Systematic Review and Meta-analysis
Research Original Investigation A Systematic Review and Meta-analysis Connor A. Emdin, HBSc; Kazem Rahimi, DM, MSc; Bruce Neal, PhD; Thomas Callender, MBChB; Vlado Perkovic, PhD; Anushka Patel, PhD IMPORTANCE
Medicines To Help You High Blood Pressure
Medicines To Help You High Blood Pressure Use this guide to help you talk to your doctor, pharmacist, or nurse about your blood pressure medicines. The guide lists all of the FDA-approved products now
Prediction of Kidney Disease Progression in Patients with Diabetes
Prediction of Kidney Disease Progression in Patients with Diabetes John Arthur, MD, PhD Medical University of South Carolina SEKDC Meeting September 8, 2012 Objectives Understand the importance of predicting
Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration
Using multiple biomarkers to predict renal and cardiovascular drug efficacy: Implications for drug development and registration Hiddo Lambers Heerspink Department of Clinical Pharmacology University Medical
InDependent Diabetes Trust
InDependent Diabetes Trust Kidneys and Diabetes Updated July 2015 Registered Company Number 3148360 Registered Charity No 1058284 Contents Introduction Healthy Kidneys Kidney disease and diabetes The use
( Diabetic nephropathy) ( Microalbuminuria ) ( Macroalbuminuria )
2006 17 99-105 2006 20-40% ( ESRD ) 30 299 mg ( ) ( 300 mgday ) DCCBs ) dihydropyridine calcium channel blockers ( non- DCCBs ( -blockers ( diuretics ) 10%) 0.8 ( 60 mlmin per 1.73 m 2 30 mlmin per 1.73
Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Number 84 Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus Summary Overview Clinical
Microalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?
Focus on CME at the University of Saskatchewan Microalbuminuria: So What s a Little Protein? By Judith T. Klassen, BSc, MD, FRCPC University of Saskatchewan Practical Management of Common Medical Problems
Coding to be more efficient and accurate
Why we need to code well! Coding to be more efficient and accurate Diabetes without Complication Diabetes with opthamologic or unspecified complication Diabetes with acute complication $1833 $2931 $3836
To Learn More: Medicines To Help You High Blood Pressure
Medicines To Help You High Blood Pressure Use this guide to help you talk to your doctor, pharmacist, or nurse about your blood pressure medicines. The guide lists all of the FDA-approved products now
Microalbuminuria: An increasingly recognized risk factor for CVD
Microalbuminuria: An increasingly recognized risk factor for CVD Long known to be associated with kidney disease, the importance of protein in the urine is now becoming recognized as a sensitive, accessible
Treating Hypertension in the Patient With Overt Diabetic Nephropathy. Edmund J. Lewis, MD
Treating Hypertension in the Patient With Overt Diabetic Nephropathy Edmund J. Lewis, MD Summary: Arterial blood pressure is a major determinant of renal and cardiovascular outcomes in diabetic nephropathy.
How High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy?
How High Should an ACE Inhibitor or Angiotensin Receptor Blocker Be Dosed in Patients with Diabetic Nephropathy? Marc S. Weinberg, MD, Nicholas Kaperonis, MD, and George L. Bakris, MD* Address *Hypertension
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) Adapted by Capital Health Plan Approved by Quality Improvement
DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Elhami et al. SJIF Impact Factor 5.210 Volume 4, Issue 11, 1159-1166 Research Article ISSN 2278 4357 DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE
Chronic Kidney Disease and Diabetes
Anyone with diabetes can get kidney disease. Diabetes and high blood pressure are the most common causes of kidney disease, and people often have both. Chronic (long term) kidney disease (CKD) caused by
HYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
Understanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
High Blood Pressure and Kidney Disease
High Blood Pressure and Kidney Disease National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH The kidneys play a key
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations
Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations Authors: Kayce Bell, Pharm.D. Candidate 2015 Harrison School of Pharmacy, Auburn University; June Twiggs, Pharm.D. Candidate 2015
Diabetes and the Kidneys
Diabetes and the Kidneys Aim(s) and objective(s) This guideline focuses on the detection, prevention, and management of kidney disease in people with diabetes. The management of end-stage renal disease
Case study 28: Managing hypertension in diabetes
Case study 28: Managing hypertension in diabetes October 2003 An Independent, Australian organisation for Quality Use of Medicines National Prescribing Service Limited ACN 082 034 393 Level 7/418A Elizabeth
GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
END ORGAN PROTECTION 3 : 9. Mangesh Tiwaskar, Mumbai
END ORGAN PROTECTION 3 : 9 Mangesh Tiwaskar, Mumbai INTRODUCTION Blood pressure and body fluid volume are mostly regulated by the renin-angiotensin system (RAS). It is evident that overactive RAS play
The incidence of cardiovascular disease (CVD)
Review Paper Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead Rigas Kalaitzidis, MD; George Bakris, MD The incidence of type 2 diabetes is increasing in the United
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases
http://www.kidney-international.org & 2011 International Society of Nephrology The contribution of chronic kidney disease to the global burden of major noncommunicable diseases William G. Couser 1, Giuseppe
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. sacubitril/valsartan film-coated tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr ENTRESTO TM sacubitril/valsartan film-coated tablets Read this carefully before you start taking ENTRESTO TM and
SAVAYSA (edoxaban) U.S. Opportunity
SAVAYSA (edoxaban) U.S. Opportunity February 17, 2015 Ken Keller President, U.S. Commercial DSI, Inc. Key Discussion Points Daiichi Sankyo, Inc. (DSI) in the U.S. SAVAYSA (edoxaban) U.S. Indication NOAC
Drug Treatment in Type 2 Diabetes with Hypertension
Hypertension is 1.5 2 times more prevalent in Type 2 diabetes (prevalence up to 80 % in diabetic subjects). This exacerbates the risk of cardiovascular disease by ~ two-fold. Drug therapy reduces the risk
Asthma Living Guideline Search Narrative - Diagnosis
Asthma Living Guideline Search Narrative - Diagnosis 13 March 2003 Searches were carried out by the HTBS. The strategies are included below. Searches were carried out on the key questions. 1. How do we
Pharmacotherapy Primer
Pharmacotherapy Primer Based on the ACC/AHA 2005 Guideline Update Learn and LiveSM Diagnosis and Management of Chronic Heart Failure in the Adult Special thanks to Distributed through support from GlaxoSmithKline.
Supplementary Online Content
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
How To Treat Diabetes Mellitus
Diabetic nephropathy: Do all patients with Diabetes Mellitus benefit from an ACE-I or ARB? Carrie Rogers, Pharm.D. PGY2 Ambulatory Care Pharmacy Resident South Texas Veterans Health Care System The University
Comprehensive Diabetes Care (CDC)
Comprehensive Diabetes Care 1 Comprehensive Diabetes Care (CDC) The percentage of members 18 75 years of age with diabetes (type 1 and type 2) who had each of the following. Hemoglobin A1c (HbA1c) testing
Measuring Generic Efficiency in Part D
Measuring in Part D Rates among Medicare Part D Generic efficiency rate is a measurement of the total number of prescrip=ons filled as a generic for products with a direct generic subs=tute within a therapeu=c
Retarding the Progression of Diabetic Nephropathy in Type 2 Diabetes Mellitus: Focus on Hypertension and Proteinuria
24 Review Article Retarding the Progression of Diabetic Nephropathy in Type 2 Diabetes Mellitus: Focus on Hypertension and Proteinuria GSL Lee, 1 MBBS, M Med (Int Med), FAMS (Renal Med) Abstract Introduction:
Department of Pharmacology, College of Medicine, University of Mosul. Department of Pharmacology, College of Pharmacy, University of Mosul
Protective Effect of Losartan in Reducing Microalbuminuria in Type 2 Diabetic Patients with Essential Hypertension Fadhil Abas Al-Hammami 1, Mohammed Najim Abed 2, Waleed Zaki Khalil 3 1 Department of
Angiotensin-converting enzyme (ACE) inhibitors Angiotensin II receptor blockers (ARBs) Beta-blockers Calcium channel blockers Diuretics
Angiotensin-converting enzyme (ACE) inhibitors Angiotensin II receptor blockers (ARBs) Beta-blockers Calcium channel blockers Diuretics This brochure gives you information about high blood pressure and
When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?
ORIGINAL PAPER When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist? Sripal Bangalore, MD, MHA; 1 Sunil Kumar, MD; 2 Franz
OUTPATIENT MANAGEMENT OF CHRONIC KIDNEY DISEASE. Jeanie Park, MD MS Assistant Professor Renal Division Emory University School of Medicine
OUTPATIENT MANAGEMENT OF CHRONIC KIDNEY DISEASE Jeanie Park, MD MS Assistant Professor Renal Division Emory University School of Medicine Disclosures None Goals Background and staging Strategies to slow
Guideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
CHAPTER 8 ANTIHYPERTENSIVE DRUGS
CHAPTER 8 ANTIHYPERTENSIVE DRUGS Classification 1. Diuretics. 2. Beta adrenergic blockers. 3. Calcium channel blockers. 4. Angiotensin converting enzyme inhibitors. 5. Angiotensin receptor blockers. 6.
The incidence of diabetes mellitus in North America
PRACTICE AT THE B EDSIDE Microalbuminuria in diabetes mellitus Sheldon W. Tobe, Philip Alan McFarlane, David Malcolm Naimark Case A 50-year-old woman with type 2 diabetes mellitus identified 5 years earlier
Pharmacologic Management of Hypertension in Patients with Diabetes
Pharmacologic Management of Hypertension in Patients with Diabetes KAREN L. WHALEN, PharmD, University of Florida College of Pharmacy St. Petersburg Campus, Seminole, Florida ROBERT D. STEWART, PharmD,
Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD
Chronic Kidney Disease and the Electronic Health Record Duaine Murphree, MD Sarah M. Thelen, MD Definition of Chronic Kidney Disease (CKD) Defined by the National Kidney Foundation Either a decline in
Hypertension Guidelines
Overview Hypertension Guidelines Aim to reduce Blood Pressure to 140/90 or less (140/80 for diabetics), adding drugs as needed until further treatment is inappropriate or declined. N.B. patients do not
Hypertension is an extremely common
Reviews/Commentaries/Position T E C H N I C A L R E V I E W Statements The Treatment of Hypertension in Adult Patients With Diabetes CARLOS ARAUZ-PACHECO, MD 1 MARIAN A. PARROTT, MD, MPH 2 PHILIP RASKIN,
Correspondence to: Rima B Shah (rima_1223@yahoo.co.in) DOI: 10.5455/ijmsph.2013.2.167-172 Received Date: 29.11.2012 Accepted Date: 03.12.
RESEARCH ARTICLE STUDY OF UTILIZATION PATTERN OF ANTI-HYPERTENSIVE DRUGS IN HYPERTENSIVE DIABETIC PATIENTS WITH OR WITHOUT REDUCED RENAL FUNCTION AT TERTIARY CARE TEACHING HOSPITAL Jay Shah 1, Tejas Khakhkhar
Position Statement Diabetic Nephropathy American Diabetes Association
Information obtained from the American Diabetes Association 2002 by the American Diabetes Association, Inc. Publication Date January 2002 in Diabetes Care 25:S85-S89, 2002 Edited by the Nephrology Department,
NCP UNCORRECTED PROOF
Reduction of proteinuria with angiotensin receptor blockers Jan Galle ARTICLE SUMMARY Renal pathophysiology is elicited by activation of angiotensin II type 1 (AT 1 ) receptors at all stages of renovascular
Type 2 diabetes mellitus is a common disease with substantial
Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Sandeep Vijan, MD, MS, and Rodney A. Hayward, MD Clinical Guidelines
The 365-day period begins with the first dispensing transaction for each Ontario Drug Benefit (ODB) recipient on or after October 1, 2015.
Ontario Public Drug Programs, Ministry of Health and Long-Term Care Chronic-use Medications List by In accordance with subsection 18 (11.1) of Ontario Regulation 201/96 made under the Ontario Drug Benefit
Cardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
Calculating the stage of Renal Disease
Calculating the stage of Renal Disease When the Refresh Template/Check Labs button is depressed, the box next to MDRD, will be automatically checked. In order to use this in the calculation of the stage
Kidney Disease WHAT IS KIDNEY DISEASE? TESTS TO DETECT OR DIAGNOSE KIDNEY DISEASE TREATMENT STRATEGIES FOR KIDNEY DISEASE
Kidney Disease WHAT IS KIDNEY DISEASE? Kidney disease is when your kidneys are damaged and not functioning as they should. When kidney disease is not going away it is called chronic kidney disease or CKD.
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis Suetonia C Palmer, Dimitris Mavridis, Eliano Navarese, Jonathan C Craig,
KDIGO THE GEORGE INSTITUTE FOR GLOBAL HEALTH. Antiocoagulation in diabetes and CKD Vlado Perkovic
THE GEORGE INSTITUTE FOR GLOBAL HEALTH Antiocoagulation in diabetes and CKD Vlado Perkovic Executive Director, George Institute Australia Professor of Medicine, University of Sydney Affiliated with the
Brand X Online Brand Pulse 2.23.2010. sample report
Brand X Online Brand Pulse 2.23.2010 sample report Table of Contents 2 Brand queries analyzed 3 Analysis frame 4 Notes 5 Comparison across online media 6-9 Blog data 10-18 Traditional media data 19-21
KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE. Supplemental Tables November 2013
KDIGO CLINICAL PRACTICE GUIDELINE FOR LIPID MANAGEMENT IN CHRONIC KIDNEY DISEASE Supplemental Tables November 2013 Suppl Table 1: Summary table of RCT examining the effect of exercise in CKD 5HD patients
Diabetes and Your Kidneys
American Kidney Fund reaching out giving hope improving lives Diabetes and Your Kidneys reaching out giving hope improving lives Diabetes: The #1 Cause of Kidney Failure Your doctor told you that you have
BASED ON WORLD Health Organization
Treating High-Risk Diabetic Hypertensive Patients With Comorbid Conditions Robert W. Schrier, MD Diabetes mellitus, a highly prevalent metabolic and vascular disease, affects 155 million people worldwide.
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
Renal Disease in Type 2 Diabetes Mellitus
Renal Disease in Type 2 Diabetes Mellitus 6th Collaborative DiGP/HSE/UCC Conference 25 th September 2013 Dr. Eoin O Sullivan Consultant Endocrinologist Bon Secours Hospital Cork Case 69 year old woman
The Stages of Chronic Kidney Disease and the Estimated Glomerular Filtration Rate
The Stages of Chronic Kidney Disease and the Estimated Glomerular Filtration Rate LAURENCE E. CARROLL, M.D., F.A.S.N. Hypertension Kidney Specialists INTRODUCTION The ability to assess kidney function
Diseases of the cardiovascular system can be
Review Paper Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know? Luis Ruilope, MD; 1 Joseph Izzo, MD; 2 Hermann Haller, MD; 3 Bernard Waeber, MD; 4 Suzanne Oparil, MD; 5 Michael
Chronic Kidney Disease: A New Classification and Staging System
Clinical Review Article Series Editor: Mark A. Perazella, MD, FACP Chronic Kidney Disease: A New Classification and Staging System Mark A. Perazella, MD, FACP Robert F. Reilly, MD Chronic kidney disease
Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한
Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한 Introduction CKD의 정의와 egfr의 측정 CKD의 risk factor와 mechanism 한국의 CKD prevalence 와 prognosis CKD의 치료와
A SHARED DECISION-MAKING PROGRAM TREATMENT CHOICES FOR CORONARY HEART DISEASE
A SHARED DECISION-MAKING PROGRAM TREATMENT CHOICES FOR CORONARY HEART DISEASE This program content, including this booklet is copyright protected by Health Dialog Services Corporation (HDSC), a related
Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
Appropriate in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Robert W Schrier*, Raymond O Estacio, Philip S Mehler and William R Hiatt SUMMARY The hypertensive and
ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM
ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM Management of Traditional Cardiovascular Risk Factors in ESRD (Hypertension, Dyslipidemia, Glycemic Control) ROBERT D. TOTO, M.D. PROFESSOR OF MEDICINE
DOI: 10.1111/jch.12237. Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension 1
ASH PAPER Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension Michael A. Weber,
Chronic Heart Failure
Chronic Heart Failure By Jo Ellen Rodgers, Pharm.D., FCCP, BCPS; and Kristen Bova Campbell, Pharm.D., BCPS Reviewed by Steven P. Dunn, Pharm.D., BCPS; and Emilie L. Karpiuk, Pharm.D., BCPS, BCOP Learning
Electronic Health Record Strategies for Pay for Performance. James O Connor MD Director of Clinical Informatics
Electronic Health Record Strategies for Pay for Performance This Title is Copy where the title would go. James O Connor MD Director of Clinical Informatics Early Days of EMR... Access to Records E&M Coding
Treating Microalbuminuria
Background Diabetic nephropathy is the most common cause of end stage renal disease (ESRD). In diabetes, high blood glucose causes glomerular hyperfiltration and triggers inflammation, oxidative damage,
HYPERTENSION: Comparison of New Guidelines
HYPERTENSION: Comparison of New Guidelines L. Brian Cross, PharmD, BCACP, CDE Vice-Chair & Associate Professor Bill Gatton College of Pharmacy Department of Pharmacy Practice Associate Professor James
Guidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
Summary HTA. HTA-Report Summary. Introduction
Summary HTA HTA-Report Summary Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure Schnell-Inderst P, Kossmann
Are there any proven therapies available for the treatment of his disease?
ACOI 2010 Case ADPCKD Shortly after being elbowed in the flank during a pickup basketball game, a 35-year-old healthy man has severe, colicky abdominal pain followed by gross hematuria. He is hospitalized,
Hypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care
Southern Derbyshire Shared Care Pathology Guidelines AKI guidelines for primary care Contents: FLOW DIAGRAM: MANAGEMENT OF PATIENTS WITH AKI DETECTED IN PRIMARY CARE...2 FLOW DIAGRAM: POST AKI MANAGEMENT
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
The Newly Developed Calcium Antagonist, Azelnidipine, Increases Drain Volume in Continuous Ambulatory Peritoneal Dialysis Patients
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hiromichi Suzuki, Tsutomu Inoue, Kazuhiro Kobayashi, Junko Shoda, Hidetomo Nakamoto Many patients undergoing continuous ambulatory peritoneal dialysis (CAPD)
Easy or complex? University Pharmacy. Pharm.D. candidates, 2011
High Blood Pressure Easy or complex? University Pharmacy Edwin Elliot, Insia Hussain Pharm.D. candidates, 2011 The evolution of mankind 2.5 mn years 50 years and we wonder why our healthcare costs are
High Blood Pressure and Chronic Kidney Disease
High Blood Pressure and Chronic Kidney Disease For People with CKD Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney
Combination Antihypertensive Therapy: When to use it Diabetes
Combination Antihypertensive Therapy: When to use it Diabetes George L. Bakris, MD, F.A.S.N., F.A.S.H. Professor of Medicine Director, ASH Comprehensive Hypertension Center The University of Chicago Medicine
Heart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
World Kidney Day 11 March 2010: we must act on diabetic kidney disease
November 11, 2009 Diabetic kidney disease: Act now or pay later Robert C Atkins and Paul Zimmet For the 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney